Latest News

Uncategorized

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) Condition: Renal Cell Carcinoma Intervention: Drug: nivolumab Purpose: Single arm, open label, phase II trial. Participants to undergo biopsy of primary tumour followed by 8 weeks of nivolumab therapy followed by nephrectomy. Nivolumab to be continued post-operatively Study […]

Uncategorized

ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase III JAVELIN Renal 101 Trial

Barcelona, Spain (UroToday.com) The sarcomatoid variant is an uncommon but highly aggressive histology of renal cell carcinoma which tends to exhibit worse outcomes relative to more common histologies like clear cell RCC with respect to VEGF targeted therapy. However, sarcomatoid renal cell carcinoma is also characterized by higher lymphocytic infiltration and PD-L1 expression relative to […]

Uncategorized

ESMO 2019: Results of the Phase II TRAXAR Study: A Randomized Phase II Trial of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma

Barcelona, Spain (UroToday.com) Antiangiogenetic therapy has long been a hallmark of the treatment paradigm for metastatic renal cell carcinoma. Endoglin is an endothelial cell surface receptor that is required for angiogenesis and is highly expressed on intertumoral endothelial cells.1 TRC105 is an IgG1 class monoclonal antibody to endoglin. In preclinical models, TRC105 was capable of […]

Uncategorized

ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-term Follow-up of Non-metastatic Patients in the STAMPEDE Randomised Trial – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Multiple studies have shown the efficacy of docetaxel in metastatic hormone-sensitive and castration-resistant prostate cancer, though there is ongoing debate regarding the impact that metastatic disease burden has on docetaxel use in the hormone-sensitive setting. The STAMPEDE group has previously presented data suggesting that docetaxel is also beneficial with regards to failure […]

Robotic Assisted Urologic Laparoscopy

Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up.

The randomized open versus robotic cystectomy (RAZOR) trial reported non-inferior 2-year progression-free survival (PFS) for robotic radical cystectomy (RARC). This update was performed with extended follow-up for 3 years to demonstrate potential differences between the approaches.

Robotic Assisted Urologic Laparoscopy

Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up.

The randomized open versus robotic cystectomy (RAZOR) trial reported non-inferior 2-year progression-free survival (PFS) for robotic radical cystectomy (RARC). This update was performed with extended follow-up for 3 years to demonstrate potential differences between the approaches.

Uncategorized

ESMO 2019: Invited Discussant: Germ Cell Tumor Studies and Renal Cell Carcinoma Disease Management Methods

Barcelona, Spain (UroToday.com) In this session at ESMO 2019, Christian Kollmannsberger, MD, discussed the following three abstracts: Refractory disease represents a critical issue in GCT management with < 5% of patients surviving. Many chemotherapeutic and targeted treatment strategies have been evaluated with low response rates highlighting an urgent need for new treatment options in this […]

Uncategorized

ESMO 2019: Preliminary Results of a Phase I/II Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC

Barcelona, Spain (UroToday.com) PSMA is overexpressed in prostate cancer with limited expression in other organs. Furthermore, prostate cancer is radiosensitive with dose-response (PSA declines and OS); dose-fractionation allows delivery of higher total dose per cycle, which may result in less radio-resistance due to repopulation compared with doses 6-12 weeks apart. The initial phase I safety results […]

Uncategorized

ESMO 2019: Preliminary Results of A Phase I/II Dose-Escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Prostate-specific membrane antigen (PSMA) is highly expressed in the vast majority of prostate cancers relative to normal prostate epithelium and other tissues, and is even more highly expressed in more aggressive and advanced prostate cancers. Lutetium is a beta-emitting therapeutic radionuclide with a relatively long half-life that has maximal tissue penetration of […]

Uncategorized

ESMO 2019: Docetaxel for Hormone-naïve Prostate Cancer: Results from Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial

Barcelona, Spain (UroToday.com) STAMPEDE previously reported that adding upfront docetaxel improved overall survival (OS) for locally advanced and metastatic patients starting long-term androgen deprivation therapy (ADT).1 At the ESMO 2019 prostate cancer session, Professor Nicholas James presented long-term outcomes for M0 patients using metastatic progression-free survival (mPFS) as primary outcome, previously shown to be a surrogate […]

X